GeneGo and Genedata Integrates their Computational Systems
News Feb 14, 2006
GeneGo Inc. and Genedata AG have announced that their computational systems have been integrated to support a seamless data analysis workflow. The workflow supports target selection and validation as well as diagnostic and biomarker applications.
"Today, drug discovery scientists handle very complex "genome wide" experimental datasets," explained Julie Bryant, Vice President of Business Development at GeneGo Inc.
"To cope with such complexity they need a variety of analytical approaches and databases not available from any single source. Therefore, cooperation between computational biology specialists is logical and beneficial for end users."
GeneGo’s flagship analytical suite, MetaCore™ combines a manually curated database of clinical and pre-clinical biology information and bioactive compounds with comprehensive pathways and network analyses.
Bryant added, "MetaCore can now be connected with Genedata Expressionist® and Genedata Phylosopher®, so mutual customers will be able to move iteratively between the software systems seamlessly and inter-operatively."
"Genedata’s open and scalable architecture provides a strong basis for integration with client and third party content," says Dr. Daniel Keesman, CEO of Genedata AG.
Expressionist is designed to enable omics data and associated information to be imported, processed and analyzed in an automated and repeatable workflow. Phylosopher has been integrated closely with MetaCore’s visualization tools to identify and prioritize pathways affected by disease.
The integrated solution achieves unrivaled standards in research information management and decision support. Dr. Keesman added, "This integration has been customer-led and helps scientists place their results in biological context, thus deriving maximum benefit from experimental data."
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE